New Millennium Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$163K Buy
6,544
+3,907
+148% +$98.5K 0.07% 74
2025
Q3
$67.2K Buy
2,637
+2,363
+862% +$58.3K 0.03% 98
2025
Q2
$6.64K Sell
274
-63
-19% -$1.47K ﹤0.01% 229
2025
Q1
$8.54K Sell
337
-187
-36% -$4.89K 0.01% 216
2024
Q4
$13.9K Buy
524
+3
+0.6% +$81 0.01% 187
2024
Q3
$15.1K Buy
521
+3
+0.6% +$88 0.01% 150
2024
Q2
$14.5K Buy
+518
New +$14.3K 0.01% 162
2024
Q1
Sell
-511
Closed -$14.7K 301
2023
Q4
$14.7K Buy
511
+2
+0.4% +$60 0.01% 174
2023
Q3
$16.9K Buy
509
+3
+0.6% +$106 0.02% 144
2023
Q2
$18.6K Sell
506
-576
-53% -$22.4K 0.02% 142
2023
Q1
$44.1K Buy
1,082
+7
+0.7% +$302 0.04% 108
2022
Q4
$55.1K Buy
1,075
+52
+5% +$2.49K 0.06% 91
2022
Q3
$45K Buy
1,023
+6
+0.6% +$292 0.05% 99
2022
Q2
$53K Buy
+1,017
New +$51.8K 0.05% 98

Other funds holding PFE

New Millennium Group's PFE Position: Q4 2025 in Review

New Millennium Group increased its Pfizer (PFE) stake by 148% in Q4 2025, buying an estimated $98.5K and bringing the position to 6,544 shares worth $163K. The position accounts for 0.07% of the portfolio, ranked #74.

New Millennium Group first reported a position in PFE in Q2 2022 and has held it in 14 quarters since. 2,905 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • New Millennium Group held 6,544 shares of Pfizer worth $163K as of Q4 2025.
  • New Millennium Group bought 3,907 Pfizer shares in Q4 2025, an estimated $98.5K.
  • Pfizer made up 0.07% of New Millennium Group's portfolio in Q4 2025, its #74 holding.
  • New Millennium Group first reported a position in Pfizer in Q2 2022 and has held it in 14 quarters since.
  • 2,905 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on New Millennium Group's 13F filing for Q4 2025, filed 6 Feb 2026.